Xebra Brands has commenced its pre-trial cultivation of cannabis in the Netherlands.
As 1 of 5 companies to be selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is endeavoring to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to €70.5 million, to co-supply all pharma-grade cannabis to be sold in the Netherlands.
Cultivation in the Netherlands is conducted in Xebra's indoor facility. Xebra's specific genetic varieties are characterized by high production, compact flowers, and fine-tasting terpene profiles, with a growth cycle of 12-16 weeks.
Rodrigo Gallardo, President of Xebra, commented, "We are pleased to have commissioned our facility ahead of schedule, allowing us to conduct a pre-trial cultivation crop cycle, prior to commencement of the formal trial in December."
For more information:
Xebra Brands
Xebrabrands.com